Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
6.19
-0.54 (-8.02%)
At close: Mar 28, 2025, 4:00 PM
6.53
+0.34 (5.57%)
After-hours: Mar 28, 2025, 7:56 PM EDT
Verastem Revenue
In the year 2024, Verastem had annual revenue of $10.00M.
Revenue (ttm)
$10.00M
Revenue Growth
n/a
P/S Ratio
22.11
Revenue / Employee
$125,000
Employees
80
Market Cap
318.70M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
VSTM News
- 5 days ago - Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025 - Business Wire
- 10 days ago - Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates - Business Wire
- 5 weeks ago - Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer - Business Wire
- 2 months ago - Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference - Business Wire
- 2 months ago - Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers - Business Wire
- 2 months ago - Verastem Oncology Names Matthew E. Ros as Chief Operating Officer - Business Wire
- 2 months ago - Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China - Business Wire
- 2 months ago - Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025 - Business Wire